Brand Name
Azilect
Generic Name
Rasagiline
View Brand Information FDA approval date: July 10, 2006
Classification: Monoamine Oxidase Inhibitor
Form: Tablet
What is Azilect (Rasagiline)?
AZILECT is indicated for the treatment of Parkinson’s disease . AZILECT, a monoamine oxidase -B inhibitor , is indicated for the treatment of Parkinson’s disease
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment